CINECA IRIS Institutional Research Information System
IRIS è la piattaforma adottata dall’Università degli Studi di Udine per gestire l’archivio aperto dei prodotti della ricerca. L’archivio contiene articoli, contributi in volume, monografie, interventi pubblicati in atti di convegno, Tesi di dottorato e altri materiali.
EnglishThe genetic predisposition to a long-term efficacy of anti-tumor necrosis factor (TNF)alpha treatment in seronegative spondyloarthritis (SpA) was investigated by analysing the possible correlation between several single nucleotide gene polymorphisms and the retention rate of anti-TNF alpha therapies. We compared patients needing to switch the first anti-TNF alpha (Sw, No. 64) within at least 12 months of follow-up with patients not needing to switch (NSw, No. 123), observing at least 6 months of treatment to establish anti-TNF alpha failure, leading to treatment change. Response to treatment was evaluated by standardised criteria (BASDAI for axial involvement, DAS28-EULAR for peripheral involvement). The TNF alpha -308 A allele and the interleukin (IL)-6 -174GG homozygosis resulted as independent biomarkers predicting survival of the first anti-TNF alpha therapy in SpA patients (P = 0.007, odds ratio (OR): 4.4, 95% confidence interval (CI) = 1.5-13.1 and P = 0.035, OR: 2.1, 95% CI = 1.1-4.4). Also, the male gender (P = 0.001, OR: 3.4, 95% CI = 1.6-7.1) associated with the NSw phenotype, whereas no association was found either with the specific diagnosis or the predominant joint involvement.
The-308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis / Fabris, M.; Quartuccio, L.; Fabro, C.; Sacco, S.; Lombardi, S.; Ramonda, R.; Biasi, D.; Punzi, D.; Adami, S.; Olivieri, I.; Curcio, F.; De Vita, S.. - In: PHARMACOGENOMICS JOURNAL. - ISSN 1470-269X. - STAMPA. - 16:3(2016), pp. 238-242.
| Titolo: | The-308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis |
| Autori: | |
| Data di pubblicazione: | 2016 |
| Rivista: | |
| Citazione: | The-308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis / Fabris, M.; Quartuccio, L.; Fabro, C.; Sacco, S.; Lombardi, S.; Ramonda, R.; Biasi, D.; Punzi, D.; Adami, S.; Olivieri, I.; Curcio, F.; De Vita, S.. - In: PHARMACOGENOMICS JOURNAL. - ISSN 1470-269X. - STAMPA. - 16:3(2016), pp. 238-242. |
| Abstract: | The genetic predisposition to a long-term efficacy of anti-tumor necrosis factor (TNF)alpha treatment in seronegative spondyloarthritis (SpA) was investigated by analysing the possible correlation between several single nucleotide gene polymorphisms and the retention rate of anti-TNF alpha therapies. We compared patients needing to switch the first anti-TNF alpha (Sw, No. 64) within at least 12 months of follow-up with patients not needing to switch (NSw, No. 123), observing at least 6 months of treatment to establish anti-TNF alpha failure, leading to treatment change. Response to treatment was evaluated by standardised criteria (BASDAI for axial involvement, DAS28-EULAR for peripheral involvement). The TNF alpha -308 A allele and the interleukin (IL)-6 -174GG homozygosis resulted as independent biomarkers predicting survival of the first anti-TNF alpha therapy in SpA patients (P = 0.007, odds ratio (OR): 4.4, 95% confidence interval (CI) = 1.5-13.1 and P = 0.035, OR: 2.1, 95% CI = 1.1-4.4). Also, the male gender (P = 0.001, OR: 3.4, 95% CI = 1.6-7.1) associated with the NSw phenotype, whereas no association was found either with the specific diagnosis or the predominant joint involvement. |
| Handle: | http://hdl.handle.net/11390/1107857 |
| Appare nelle tipologie: | 1.1 Articolo in rivista |
File in questo prodotto:
http://hdl.handle.net/11390/1107857
Copyright © 2021